IP Library Granted Patent US 11,318,043
Granted Patent B2
US 11,318,043 · App. 16/095,680 · Granted May 3, 2022

Bioresorbable ocular drug delivery device

Inventors: Harold Alexander Heitzmann (Irvine, CA); David Steven Haffner (Mission Viejo, CA); Kenneth Martin Curry (Oceanside, CA); Thomas W. Burns (Dana Point, CA)
Assignee: DOSE MEDICAL CORPORATION
A61F9/0017A61F2210/0004A61F2250/0068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,318,043
App. No.
16/095,680
Granted
May 3, 2022
Kind
B2
Abstract

An ocular implant configured for implantation into the eye of a subject comprising an elongate outer shell ( 54 ), an internal plug ( 210 ) including a hydrogel and a drug reservoir including a drug ( 62 ) wherein the drug is configured to pass through at least a portion of the internal plug to control elution of the drug through the outer shell. The implant is made of biodegradable materials.

Claims (17)

1. An ocular implant configured for implantation into the eye of a subject comprising:

an elongate outer shell comprising a bioerodible material and shaped to define an interior lumen, the elongate outer shell comprising a closed rounded proximal end and a rounded distal end;

an internal plug positioned within the interior lumen; and

a drug reservoir positioned within the interior lumen and completely surrounded by the internal plug, the drug reservoir including a drug,

wherein the drug is configured to pass through at least a portion of the internal plug to control elution of the drug through the outer shell.

2. The ocular implant of claim 1 , wherein the internal plug is positioned adjacent a distal-most end of the interior lumen.

3. The ocular implant of claim 1 , wherein the elongate outer shell comprises one or more orifices positioned near a distal end of the outer shell, wherein the orifices are configured to control elution of the drug through the internal plug and out of the implant.

4. The ocular implant of claim 1 , further comprising a coating surrounding at least a portion of the outer shell.

5. The ocular implant of claim 1 , wherein the proximal end comprises an end cap.

6. The ocular implant of claim 1 , wherein the outer shell is configured to begin to bioerode after all or substantially all of the drug is eluted from the interior lumen of the implant.

7. The ocular implant of claim 1 , wherein the outer shell is configured to begin to bioerode while at least a portion of the drug to be eluted from the interior lumen of the implant remains in the interior lumen.

8. An ocular implant according to claim 1 , wherein the implant further comprises a fluid flow passageway.

9. The ocular implant of claim 8 , wherein the implant is configured for implantation within the eye of a subject, and wherein the fluid flow passageway drains ocular fluid to a physiological outflow space.

10. The ocular implant of claim 1 , wherein the implant is positioned inside a lumen of a 23-25 Gauge needle or cannula of a delivery device.

11. The ocular implant of claim 1 , wherein the implant is capsule-shaped.

12. The ocular implant of claim 1 , wherein the ocular implant is positioned in the vitreous cavity.

13. The ocular implant of claim 1 , wherein one or more orifices positioned at or near the distal end of the outer shell and one or more orifices positioned at or near the proximal end of the outer shell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2025
From: DOSE MEDICAL CORPORATION
To: GLAUKOS CORPORATION
Reel/Frame 070066/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2022
From: HEITZMANN, HAROLD ALEXANDER; HAFFNER, DAVID STEVEN; CURRY, KENNETH MARTIN; BURNS, THOMAS W.
To: DOSE MEDICAL CORPORATION
Reel/Frame 059241/0634 →
Continuity (2)
Provisional Application 62325378 · Apr 20, 2016
Related Publication 20190125581A1 · May 2, 2019
Cited By (18)
US 1,137,672 US 12,201,555 US 12,201,557 US 12,208,034 US 12,226,308 US 12,279,822 US 12,343,288 US 12,376,989 US 12,414,798 US 12,419,783 US 12,427,057 US 12,478,503 US 12,478,504 US 12,575,972 US 12,589,025 US 12,599,497 US 12,667,486 US 12,702,294